FDA approves bevacizumab biosimilar ‘bevacizumab-tnjn’ for lung and colorectal cancer
Credit: U.S. Food and Drug Administration The U.S. Food and Drug Administration (FDA) has approved Bio-Thera Solutions’ bevacizumab (Avastin) biosimilar, bevacizumab-tnjn (Avzivi), for the treatment of lung and colorectal cancer.1 The decision marks Bio-Thera Solutions’ second FDA-approved product in the United States. The decision, announced on December 7, 2023, was based on both clinical and […]
Tip sheet: Health disparities in colorectal cancer, caregiver stories, new ways to study old tumor samples, and Lung Cancer Awareness Month
SEATTLE — November 2, 2023 — Below is a summary of recent research findings and other news from Fred Hutchinson Cancer Center. November is Lung Cancer Awareness Month. If you are looking for resources, please see our media tip sheet and contact us at hplatisha@fredhutch.org. To set up an interview. Do you want to cover […]